Association of Immune-activation and Senescence Markers with Non-AIDS-defining Comorbidities in HIV-suppressed Patients
Overview
Authors
Affiliations
Objectives: We studied the link between T-cell activation, differentiation and senescence phenotypes and non-AIDS-related comorbidities in HIV-suppressed patients.
Design: Patients included in the ANRS CO3 Aquitaine Cohort were consecutively enrolled in this cross-sectional study between October 2011 and May 2013 called Chronic Immune Activation and Senescence (CIADIS) study.
Methods: We summarized immune markers [CD4 and CD8 activation (DR), differentiation (naive and terminally differentiated memory T cells), and senescence (CD57CD28)] in a weighted immune score by principal component analysis called CIADIS. Previously described Veterans Aging Cohort Study (VACS) index and immune risk profile (IRP) scores were calculated. We used adjusted logistic regression to assess the association between the CIADIS score and the presence of at least three non-AIDS-defining comorbidities.
Results: Of 876 patients with an undetectable viral load, 73.4% were men and median age was 50.5 years [interquartile range (IQR) 44.7-56.7 years]. Median CD4 T-cell count was 579/μl (IQR 429-759 cells/μl), and median duration of HIV viral suppression was 5.3 years (IQR 2.3-8.7). The weighted CIADIS score was associated with at least three comorbidities (odds ratio 1.3 for 1 SD more, 95% confidence interval 1.0, 1.6) independently of age, sex, AIDS stage, and the Veterans Aging Cohort Study score. The CIADIS and the immune risk profile scores were significantly associated with at least three comorbidities in adjusted models restricted to patients younger than 60 years. None of the tested scores were associated with at least three comorbidities in patients older than 60 years.
Conclusions: The weighted CIADIS score based on activation, senescence, and differentiation markers might help physicians identifying patients at a higher risk for non-AIDS-related comorbidities.
Li L, Yu F, Yang S, Li H, Tang Y, Ma C BMC Infect Dis. 2025; 25(1):290.
PMID: 40021989 PMC: 11869689. DOI: 10.1186/s12879-025-10511-7.
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Munoz-Muela E, Alvarez-Rios A, Lozano C Front Immunol. 2024; 15:1423734.
PMID: 39055703 PMC: 11269217. DOI: 10.3389/fimmu.2024.1423734.
Caetano D, Toledo T, de Lima A, Giacoia-Gripp C, de Almeida D, de Lima S Vaccines (Basel). 2024; 12(6).
PMID: 38932307 PMC: 11209244. DOI: 10.3390/vaccines12060578.
Nakanjako D, Nabatanzi R, Ssinabulya I, Bayigga L, Kiragga A, Banturaki G Heliyon. 2024; 10(11):e31910.
PMID: 38882354 PMC: 11177148. DOI: 10.1016/j.heliyon.2024.e31910.
Morton Z, Mehta C, Wang T, Palella F, Naggie S, Golub E Open Forum Infect Dis. 2023; 10(2):ofac702.
PMID: 36751648 PMC: 9897021. DOI: 10.1093/ofid/ofac702.